SCHEMBL1340348

SCHEMBL1340348

CC(C)COc1ccccc1NC(=O)C(=O)Nc1nc(CC(=O)O)c(Sc2ccccn2)s1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GCK P35557 5/20 0.42
SMN1; SMN2 Q16637 6/20 0.37
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
GAA P10253 1/20 0.34
MAPT P10636 3/20 0.34
THRB P10828 1/20 0.34
MYC P01106 1/20 0.33
MAX P61244 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
SCD O00767 1/20 0.33
POLB P06746 1/20 0.33
TP53 P04637 1/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1341013 0.92 GCK (0.41) GCKSMN1; SMN2ALDH1A1KDM4ENPC1
SCHEMBL1343525 0.92 GCK (0.44) GCKSMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL1342262 0.91 GCK (0.40) GCKSMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL1342228 0.87 SMN1; SMN2 (0.36) GCKSMN1; SMN2ALDH1A1KDM4ENPC1
SCHEMBL1340109 0.87 CYP2C19 (0.37) SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A
SCHEMBL1342672 0.86 GCK (0.45) GCKSMN1; SMN2ALDH1A1KDM4ENPC1
SCHEMBL1343330 0.86 TSHR (0.35) GCKSMN1; SMN2ALDH1A1KDM4ENPC1
SCHEMBL1342669 0.85 GCK (0.43) GCKSMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL1343070 0.84 MAPT (0.40) GCKSMN1; SMN2ALDH1A1KDM4ENPC1
SCHEMBL1342226 0.82 SMN1; SMN2 (0.35) GCKSMN1; SMN2ALDH1A1KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 GCK 1/4885SMN1; SMN2 2958/4885ALDH1A1 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.